ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy

[1]  Xue-Feng Li,et al.  Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum‐Based Chemotherapy in Patients With Non‐Small Cell Lung Cancer: A Network Meta‐Analysis , 2017, Journal of cellular biochemistry.

[2]  V. Budach,et al.  SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  M. Parmar,et al.  Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. , 2017, The Lancet. Oncology.

[4]  E. Sturgis,et al.  Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. , 2017, Practical radiation oncology.

[5]  J. Błasiak.  DNA-Damaging Anticancer Drugs - A Perspective for DNA Repair- Oriented Therapy. , 2017, Current medicinal chemistry.

[6]  Guopei Zhang,et al.  ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway. , 2017, Chemico-biological interactions.

[7]  D. Aust,et al.  HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Jun Zhang,et al.  A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy , 2016, Cancer Chemotherapy and Pharmacology.

[9]  B. Vadhiraja,et al.  Polymorphisms in double strand break repair related genes influence radiosensitivity phenotype in lymphocytes from healthy individuals. , 2016, DNA repair.

[10]  C. Ramos,et al.  XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation , 2016, Oncotarget.

[11]  Manolis Kellis,et al.  HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease , 2015, Nucleic Acids Res..

[12]  R. Greil,et al.  CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer , 2015, BMC Cancer.

[13]  M. Fredrikson,et al.  DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. , 2015, DNA repair.

[14]  Anuradha Bulusu,et al.  A leave-one-out cross-validation SAS macro for the identification of markers associated with survival , 2015, Comput. Biol. Medicine.

[15]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[16]  Xiao-Yu Liao,et al.  Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis , 2014, Tumor Biology.

[17]  L. Xian,et al.  The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis , 2014, Tumor Biology.

[18]  A. Olshan,et al.  Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival , 2014, Cancer Causes & Control.

[19]  H. Guchelaar,et al.  Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. , 2013, Pharmacogenomics.

[20]  Richard Simon,et al.  Overfitting in prediction models - is it a problem only in high dimensions? , 2013, Contemporary clinical trials.

[21]  Q. Wei,et al.  Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx , 2013, International journal of cancer.

[22]  A. Egloff,et al.  Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): Who would benefit from chemoradiation after surgery? , 2012, The Laryngoscope.

[23]  J. Robert,et al.  Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. , 2012, Carcinogenesis.

[24]  A. Azad,et al.  Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival , 2011, Clinical Cancer Research.

[25]  Manolis Kellis,et al.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..

[26]  D. Shriner.  Approximate and exact tests of Hardy‐Weinberg equilibrium using uncertain genotypes , 2011, Genetic epidemiology.

[27]  S. Zhong,et al.  Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) Polymorphism on Outcome of Advanced-Stage Squamous Cell Carcinoma of the Head and Neck Are Treatment Dependent , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[28]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[29]  H. Thierens,et al.  Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. , 2009, International journal of radiation oncology, biology, physics.

[30]  A. Ziegler,et al.  A Genotype-Based Approach to Assessing the Association between Single Nucleotide Polymorphisms , 2008, Human Heredity.

[31]  J. Carles,et al.  Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. , 2006, International journal of radiation oncology, biology, physics.

[32]  J. Thompson,et al.  The choice of a genetic model in the meta-analysis of molecular association studies. , 2005, International journal of epidemiology.

[33]  J. Luketich,et al.  Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. , 2003, Carcinogenesis.

[34]  Y. Pommier,et al.  Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. , 2002, Cancer research.

[35]  R. Parshad,et al.  XPD polymorphisms: effects on DNA repair proficiency. , 2000, Carcinogenesis.

[36]  M S Pepe,et al.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. , 1989, Biometrics.

[37]  M. Sydes,et al.  Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. , 2012, The Lancet. Oncology.